特利加压素联合普奈洛尔对肝硬化上消化道出血患者血压及血流动力学指标的影响

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the effects of Terlipressin combined with Propranolol on blood pressure and hemodynamics indexes in patients with upper gastrointestinal bleeding (UGB) in liver cirrhosis. Methods The clinical data of 112 patients with UGB with liver cirrhosis in Qianjiang Central Hospital from February 2019 to February 2021 were retrospectively analyzed. They were divided into reference group and experimental group according to different treatment methods, 56 patients in the reference group were treated with propranolol, and 56 patients in the experimental group were treated Terlipressin combined with Pranolol treatment, the clinical efficacy, blood pressure and hemodynamics between the two groups were compared. Results The total clinical effective rate (96.43%) of the test group was higher than the reference group(75.00%),and the difference was statistically significant (P＜0.05).The systolic blood pressure ([130.62±5.31]ml/min) after treatment in the test group was higher than the reference group (119.26±2.05) ml/min,diastolic blood pressure ([90.52±5.13]ml/min) was higher than the control group ([78.26±4.27]ml/min), the differences were statistically significant (P＜0.05). The portal vein (PV) blood flow ([705.26±13.62]ml/min) of the experimental group after treatment was less than the control group([846.26±18.62]ml/min),the PV blood flow velocity of the test group([13.26±1.05]cm/min) was slower than the control group ([17.62±2.11]cm/min), and the PV inner diameter ([9.13±1.62]mm) was shorter than that of the reference group ([13.82±2.17]mm), the differences were statistically significant (P＜0.05). Conclusion Terlipressin combined with Pranolol can effectively reduce the amount of bleeding in UGB patients with liver cirrhosis and maintain hemodynamic stability.

Key words： Terlipressin Propranolol Liver cirrhosis Upper gastrointestinal bleeding Hemodynamics

Received: 05 August 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I35/54

[1]	琚绍静，刘伟，刘斌，等.垂体后叶素联合普萘洛尔治疗肝硬化并发上消化道出血的疗效观察和护理体会[J].安徽医药，2017，21（1）：169-172.
[2]	施媛，张仪，胡月.奥曲肽联合普萘洛尔治疗肝硬化上消化道出血的疗效和对脾静脉与门静脉内径及血流的影响[J].医学临床研究，2018，35（8）：1575-1577.
[3]	王鹏，王波，南鹏，等.奥曲肽联合普萘洛尔治疗肝硬化上消化道出血的疗效及对血流动力学的影响[J].中国临床医生杂志，2019，47（3）：292-294.
[4]	刘慧，张诒凤，郁磊.特利加压素联合生长抑素治疗肝硬化并发上消化道出血患者疗效研究[J].实用肝脏病杂志，2020，23（6）：857-860.
[5]	中华医学会肝病学分会.肝硬化诊治指南[J].中华肝脏病杂志，2019，27（11）：846-865.
[6]	中华内科杂志编辑委员会，《中华医学杂志》编辑委员会，《中华消化杂志》编辑委员会，等.急性非静脉曲张性上消化道出血诊治指南（2018 年，杭州）[J].中华内科杂志，2019，58（3）：173-180.
[7]	夏正新，张志飞.特利加压素联合生长抑素治疗肝硬化失代偿期并急性上消化道大出血的疗效观察[J].药物评价研究，2017，40（12）：1745-1748.
[8]	周筱燕，周岩芬，杨辉.奥曲肽分别与垂体后叶素和特利加压素联用对肝硬化合并上消化道出血患者实验室指标的影响研究[J].临床和实验医学杂志，2017，16（24）：2451-2454.
[9]	庞国宏，李灵军，杨汝磊.特利加压素联合埃索美拉唑治疗肝硬化上消化道出血患者肝静脉压力梯度的变化[J].实用肝脏病杂志，2017，20（3）：364-365.
[10]	程远，兰宇，贾绮滨.特利加压素对肝硬化上消化道出血患者血流动力学的影响[J].临床和实验医学杂志，2018，17（22）：2419-2422.
[11]	李晓路，丁惠国，曾阿娟，等.特利加压素联合生长抑素治疗肝硬化食管胃静脉曲张出血的效果分析[J].临床肝胆病杂志，2020，36（6）：1273-1277.
[12]	龚敏，王桂良，林秋满，等.早期生长抑素和/或特利加压素联合内镜处理治疗肝硬化食管胃底静脉曲张破裂出血效果研究[J].中国全科医学，2019，22（36）：4439-4446，4452.
[13]	华鹏，崔翔，周荣赛，等.奥曲肽联合普萘洛尔治疗肝硬化上消化道出血患者效果及对炎性指标水平和门、脾静脉血流影响[J].临床误诊误治，2020，33（5）：44-48.
[14]	郑宏波，王山军，刘小莹.奥曲肽与特利加压素联合泮托拉唑对肝硬化上消化道出血患者止血效果、肝静脉压指标及再出血率的影响[J].肝脏，2018，23（9）：837-839.
[15]	鄢冬梅，鄢长秀.还原型谷胱甘肽联合生长抑素治疗肝硬化合并上消化道出血的疗效及对血液流变学的影响[J].检验医学与临床，2020，17（18）：2711-2714.
[16]	陈玉英.持续静滴特利加压素与奥曲肽在治疗食管胃底静脉曲张破裂出血的疗效比较[J].中国医药科学，2012，2（11）：61，68.